Tech Coloproctol. 2025 Dec 8;30(1):6. doi: 10.1007/s10151-025-03236-x.
ABSTRACT
INTRODUCTION: Limited data exists in literature regarding concomitant ventral rectopexy (VRP) and sacrocolpo/hysteropexy (SCP/SHP), with existing studies being predominantly retrospective. The aim of this meta-analysis is to assess the anatomical and functional outcomes of combined VRP and SCP/SHP for the treatment of multicompartmental pelvic organ prolapse (POP).
METHODS: We performed systematic research and meta-analysis from PubMed/MEDLINE and EMBASE, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, until 15 January 2025. Women submitted to VRP with SCP/SHP were included. Improvement of anorectal symptoms were evaluated. Postoperative anatomical relapse was reported. Re-operation rates were evaluated.
RESULTS: Six articles were included. Constipation/obstructed defecation syndrome (ODS) [odds ratio (OR) 0.26, 95% CI 0.10-0.68; p = 0.006 (I2 test 81%, p = 0.56)] and of anal/fecal incontinence (AI/FI) rates [OR 0.09, 95% CI 0.03-0.30; p < 0.0001 (I2 test 70%, p = 0.04)] significantly improved after combined VRP and SCP/SHP. The proportion metanalysis of four included studies reported a subjective POP recurrence rate of 7% (95% CI 1-13%; I2 test 82.9%, p < 0.001). The proportion metanalysis of five included studies for objective POP recurrence was 5% (95% CI 1-9%; I2 test 56.9%, p = 0.041). No serious adverse events were reported.
CONCLUSIONS: VRP combined with SCP/SHP has been shown to be safe and effective for women with multicompartment POP, providing optimal anatomical and functional outcomes. Larger, long-term, prospective-controlled studies are needed to confirm these results.
PMID:41359190 | DOI:10.1007/s10151-025-03236-x
